At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 190 enrolled
Drug / intervention
Ruxolitinib Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
In Brief
A Phase 3 clinical trial evaluating Ruxolitinib Cream and Vehicle Cream for Prurigo Nodularis. Completed, enrolled 190 participants across 76 sites in 13 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesAustralia, Austria, Bulgaria, Canada, Denmark, France, Germany, Italy, Poland, South Korea, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedMar 2023
Enrollment StartJun 2023
Primary CompletionDec 2024
Study CompletionNov 2025
TodayJul 2026
First PostedMar 10, 2023
Enrollment StartJun 12, 2023
Primary CompletionDec 30, 2024
Study CompletionNov 4, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.3 years ago
Interventions
Ruxolitinib Creamdrug
Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
Vehicle Creamdrug
Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.